Penton, H.
hdl.handle.net/2105/62521
Master Health Economics, Policy and Law
Erasmus School of Health Policy & Management

Scheffer Apecechea, N.J. (2021, July 16). What is the cost-effectiveness of veliparib in combination with carboplatin and paclitaxel, compared to carboplatin with paclitaxel only, for patients with BRCA-positive, triple-negative, or HER2-negative, advanced breast cancer, who received up to two chemotherapy regimens for advanced disease, in the UK?. Master Health Economics, Policy and Law. Retrieved from http://hdl.handle.net/2105/62521